Skip to content

Lidocaine intravenous closed treatment of severe atopic dermatitis exacerbation: multi-center, double-blind, randomized, placebo-controlled study

Lidocaine intravenous closed treatment of severe atopic dermatitis exacerbation: multi-center, double-blind, randomized, placebo-controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002590
Enrollment
Unknown
Registered
2012-09-16
Start date
2012-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

test group:Lidocaine Hydrochloride Injection
control group:sodium chloride solution

Sponsors

The First Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) The age of 14 to 65 years old, male or female; (2) according to Hanifin and Rajka diagnostic criteria for diagnosis of atopic dermatitis; (3) SCORAD objective score 40 points or more, severe atopic dermatitis; (4) researchers overall score (IGA) >=4 points; (5) conventional therapy (topical strong effect of glucocorticoid hormones or immune regulation, etc.) can not effectively control the disease; (6) stable vital signs; (7) have signed informed consent.

Exclusion criteria

Exclusion criteria: (1) those who are allergic to lidocaine or other local anesthetics; (2) abnormal liver and kidney function: AST, ALT, or serum creatinine values greater than the upper limit of normal; (3) severe heart disease (such as atrioventricular block or severe bradycardia); (4) history of epilepsy; (5) phototherapy, systemic sugar corticosteroids or immunosuppressants (such as cyclosporine, azathioprine, or immunoglobulin) treatment within 3 months, and at the same time, participate in other clinical researchers; (6) malignancy or other chronic infected person; (7) the subjects to be judged unbeleivable or will be poor comliance.

Design outcomes

Primary

MeasureTime frame
Scoring Atopic Dermatitis;Investigator’s global assessement;

Secondary

MeasureTime frame
Clinical evaluation of patients;Dermatology Life Quality Index;

Countries

China

Contacts

Public ContactXing-hua Gao
gaobarry@hotmail.com+86 13940152467

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026